DCT and melanoma: The authors suggest that MET, along with other molecules (i.e., TYRP2, VLA-4, HSP70, and an HSP90 isoform) could represent a specific melanoma signature in circulating EXOs, in patients with advanced melanoma, that could be used as a metastatic disease indicator [10].